Holen Sie sich die Stockscreener-App
0.593
3.13%
0.018
Schlusskurs vom Vortag:
$0.575
Offen:
$0.59
24-Stunden-Volumen:
5.56M
Relative Volume:
0.42
Marktkapitalisierung:
$144.36M
Einnahmen:
$424.90K
Nettoeinkommen (Verlust:
$-94.02M
KGV:
-0.2387
EPS:
-2.4842
Netto-Cashflow:
$-51.25M
1W Leistung:
-7.27%
1M Leistung:
-5.32%
6M Leistung:
+170.78%
1J Leistung:
-44.58%
1-Tages-Spanne:
$0.5723
$0.6067
1-Wochen-Bereich:
$0.5314
$0.6379
52-Wochen-Spanne:
$0.1611
$2.5375
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.593 | 155.68M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics (OTLK) Seeks Permanent J-Code for LYTENAVA to Boost U.S. Commercial Launch - GuruFocus
Outlook Therapeutics applies for permanent J-code for LYTENAVA By Investing.com - Investing.com Canada
Outlook Therapeutics Submits HCPCS Level II Application to - GlobeNewswire
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Cash per share of Outlook Therapeutics, Inc. – HAN:41O - TradingView
Outlook Therapeutics, Inc. Revenue Breakdown – HAN:41O - TradingView
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - stocktwits.com
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) added to S&P Global BMI Index - marketscreener.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Outlook Therapeutics (OTLK) Edges Higher, Holding Above $0.65 SupportRatio Spread Trade - careplusvn.com
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Australia
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - investing.com
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment - marketscreener.com
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect Segment - 富途牛牛
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - stocktitan.net
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics Appoints Kevin Lundquist as CFO - Yahoo Finance
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Outlook Therapeutics Inc-Aktie (OTLK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sukhtian Faisal Ghiath | Director |
Jul 29 '26 |
Buy |
1.05 |
95,398 |
99,996 |
220,972 |
| Haddadin Yezan Munther | Director |
Jun 02 '26 |
Buy |
0.83 |
29,000 |
24,145 |
66,167 |
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):